Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

By Yansheng Du, Zhizhong Ma, Suizhen Lin, R. Dodel, F. Gao, K. Bales, L. C. Triarhou, E. Chernet, K. Perry, David L. Nelson and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

800 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/d228d78cd7b62a3d55f36943aa9c493db646610b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Linda R. Watkins
2. S. Maier
3. E. Milligan
4. M. Tansey
5. M. Goldberg
6. Jau-Shyong Hong
7. P. Whitton
8. R. Ji

In Neurology

1. Linda R. Watkins
2. M. Tansey
3. M. Goldberg
4. P. Whitton
5. S. Maier
6. Jau-Shyong Hong
7. Bin Liu
8. E. Milligan

Citations in the corpus

• Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia (2008, background): “This is relevant because minocycline attenuates neuroinflammation in several rodent models of disease including Amyotrophic Lateral Sclerosis [46], Experimental Autoimmune Encephalomyelitis (EAE) [45] and MPTP-induced Parkinson's disease [47].”
• Minocycline: far beyond an antibiotic (2013, background): “…et al., 2001) and neuropathic pain (Raghavendra et al., 2003; Mei et al., 2011), and of several neurodegenerative conditions such as Parkinson’s (Du et al., 2001; Thomas and Le, 2004; Abdel-Salam, 2008) and Huntington’s (Chen et al., 2000; Thomas et al., 2004) diseases, amyotrophic lateral…”
• Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy (2015, background): “Antioxidants can inhibit inflammatory responses and protect dopaminergic neurons as reported in laboratory and animal models of PD [78-84].”
• Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy (2003, background): “In vivo and in vitro studies showed that minocycline provides neuroprotection by inhibiting microglial activation under various pathological conditions without affecting neurons, astroglia, or oligodendroglial progenitors (Amin et al., 1996; Yrjanheikki et al., 1998; Du et al., 2001; Tikka and Koist”
• Oxidative stress in neurodegeneration: cause or consequence? (2004, background): “Minocycline, which is believed to act in part by blocking the activity of iNOS, has been shown to prevent neurodegeneration both in ALS–SOD transgenic mice and in wild-type mice after MPTP administration, although this claim has been disputed in the latter cas”
• Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation (2005, background): “Although effects of minocycline on p38 MAPK activity in cultured neurons have been described (Du et al., 2001; Lin et al., 2001), in mixed spinal cord cultures excitotoxins activated p38 MAPK exclusively in microglial cells, which was inhibited by minocycline (Tikka and Koistinaho, 2001; Tikka et al”
• Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention (2009, result): “For example, in some studies it was shown to be neuroprotective against MPTP-, LPS- and 6- OHDA-induced nigral DA neuron loss (Du et al., 2001; He et al., 2001; Wu et al., 2002; TomasCamardiel et al., 2004) while in others it exacerbated the effects of MPTP in rodents and nonhuman primates (Yang et…”
• Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention (2003, background): “For example, mice lacking inducible nitric oxide synthase activity are resistant to MPTP-induced lesions and inhibition of microglial activation reduces MPTP neurotoxicity (Itzhak et al., 1999; Liberatore et al., 1999; Dehmer et al., 2000; Du et al., 2001; Wu et al., 2002).”
• Inflammation as a causative factor in the aetiology of Parkinson's disease (2007, background): “minocycline was shown to have neuroprotective effects on dopaminergic neurons in MPTP, LPS and 6-OHDA models of PD (Du et al., 2001; He et al., 2001; Wu et al., 2002; TomasCamardiel et al., 2004).”